[Childhood Interstitial Lung Disease in Infancy. Classification, diagnosis and management].
Identifieur interne : 000263 ( Main/Exploration ); précédent : 000262; suivant : 000264[Childhood Interstitial Lung Disease in Infancy. Classification, diagnosis and management].
Auteurs :Source :
- Archivos argentinos de pediatria [ 1668-3501 ] ; 2019.
Abstract
Childhood interstitial lung diseases, which some authors refer to as diffuse diseases of the lung, constitute a group of entities that are characterized by remodeling of the interstitium and distal airspaces that cause disturbances of gas exchange in the lungs. While some entities have few symptoms and naturally evolve favorably, others are potentially lethal. Its etiology is very varied, including forms of genetic cause, infectious origin, associated with systemic diseases, drugs and some remain of unknown origin. At present, the development of genetic testing allows diagnosing a group of pathologies, avoiding sometimes a lung biopsy. Its treatment includes different immunosuppressive and immunomodulatory drugs, mainly corticosteroids and hydroxychloroquine, which aim to reduce inflammation, stabilize the disease and prevent the phenomena of remodeling and fibrosis. This consensus is focused on children under 2 years of age, because most of the new entities recently described are manifested at this age.
DOI: 10.5546/aap.2019.S120
PubMed: 31833343
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000014
- to stream PubMed, to step Curation: 000014
- to stream PubMed, to step Checkpoint: 000019
- to stream Ncbi, to step Merge: 000D17
- to stream Ncbi, to step Curation: 000D17
- to stream Ncbi, to step Checkpoint: 000D17
- to stream Main, to step Merge: 000263
- to stream Main, to step Curation: 000263
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[Childhood Interstitial Lung Disease in Infancy. Classification, diagnosis and management].</title></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2019">2019</date><idno type="RBID">pubmed:31833343</idno><idno type="pmid">31833343</idno><idno type="doi">10.5546/aap.2019.S120</idno><idno type="wicri:Area/PubMed/Corpus">000014</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000014</idno><idno type="wicri:Area/PubMed/Curation">000014</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000014</idno><idno type="wicri:Area/PubMed/Checkpoint">000019</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000019</idno><idno type="wicri:Area/Ncbi/Merge">000D17</idno><idno type="wicri:Area/Ncbi/Curation">000D17</idno><idno type="wicri:Area/Ncbi/Checkpoint">000D17</idno><idno type="wicri:Area/Main/Merge">000263</idno><idno type="wicri:Area/Main/Curation">000263</idno><idno type="wicri:Area/Main/Exploration">000263</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">[Childhood Interstitial Lung Disease in Infancy. Classification, diagnosis and management].</title></analytic><series><title level="j">Archivos argentinos de pediatria</title><idno type="eISSN">1668-3501</idno><imprint><date when="2019" type="published">2019</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Childhood interstitial lung diseases, which some authors refer to as diffuse diseases of the lung, constitute a group of entities that are characterized by remodeling of the interstitium and distal airspaces that cause disturbances of gas exchange in the lungs. While some entities have few symptoms and naturally evolve favorably, others are potentially lethal. Its etiology is very varied, including forms of genetic cause, infectious origin, associated with systemic diseases, drugs and some remain of unknown origin. At present, the development of genetic testing allows diagnosing a group of pathologies, avoiding sometimes a lung biopsy. Its treatment includes different immunosuppressive and immunomodulatory drugs, mainly corticosteroids and hydroxychloroquine, which aim to reduce inflammation, stabilize the disease and prevent the phenomena of remodeling and fibrosis. This consensus is focused on children under 2 years of age, because most of the new entities recently described are manifested at this age.</div></front></TEI><affiliations><list></list><tree></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000263 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000263 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:31833343
|texte= [Childhood Interstitial Lung Disease in Infancy. Classification, diagnosis and management].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:31833343" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ChloroquineV1
| This area was generated with Dilib version V0.6.33. |  |